Results 31 to 40 of about 3,015 (158)
The Obstetrician &Gynaecologist, Volume 27, Issue 3, Page 180-196, July 2025.Key content The epidemiology and pathophysiology of AFLP, HELLP syndrome and infectious viral hepatitis in late pregnancy. Clinical presentation, diagnosis and management of these conditions. Complications (maternal and fetal) and how these can be managed. The role of a multidisciplinary team in management.
Victor N. Chilaka +4 more
wiley +1 more source
Journal of Viral Hepatitis, Volume 32, Issue 4, April 2025.ABSTRACT Chronic hepatitis C virus (HCV) infection can be associated with neuropsychiatric symptoms like fatigue and cognitive impairment, independent of the liver status. The present study aims to assess changes in the pattern and extent of neuropsychological symptoms after successful treatment with interferon (IFN)‐based and IFN‐free therapy.
Meike Dirks +10 more
wiley +1 more source
New treatments for genotype 1 chronic hepatitis C – focus on simeprevir
Therapeutics and Clinical Risk Management, 2014 Tatsuo Kanda, Shingo Nakamoto, Shuang Wu, Osamu Yokosuka Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, Chiba, Japan Abstract: Chronic hepatitis C virus (HCV) infection causes end-stage liver diseases and ...
Kanda T, Nakamoto S, Wu S, Yokosuka O
doaj
MedComm, Volume 6, Issue 3, March 2025.The malignant transformation from chronic viral hepatitis to hepatocellular carcinoma (HCC) involves intricate interactions among viral, host, and environmental factors. Key drivers of this transformation include viral integration, genomic instability, epigenetic modifications, oxidative stress, gut microbiota dysbiosis, chronic inflammation, immune ...
Huimin Yuan +6 more
wiley +1 more source
Simeprevir for the treatment of hepatitis C virus infection
Pharmacogenomics and Personalized Medicine, 2014 Laure Izquierdo,1 François Helle,1 Catherine François,1,2 Sandrine Castelain,1,2 Gilles Duverlie,1,2 Etienne Brochot1,2 1Virology Research Unit, Jules Verne University of Picardie, 2Department of Virology, Amiens University Hospital, Amiens,
Izquierdo L +5 more
doaj
Virology Journal, 2018 Background Simeprevir is approved with pegylated interferon and ribavirin (PR) for chronic hepatitis C virus (HCV) genotype (GT) 1 and GT4 infection in the USA and the European Union.
Fabien Zoulim +11 more
doaj +1 more source
Egyptian Rheumatology and Rehabilitation, 2020 Background To study the most common rheumatologic manifestations of hepatitis C viral (HCV) infection in Egyptian patients and associated risk factors with assessment the effect of current therapies on these manifestations.
Hanan M. Fathi +6 more
doaj +1 more source
Reviews in Medical Virology, Volume 35, Issue 2, March 2025.ABSTRACT Alphaviruses are re‐emerging vector‐born pathogens that cause arthralgia or encephalitic diseases on a global scale. While a vaccine against chikungunya virus was recently approved, no vaccines currently exist for other alphaviruses, nor are there antiviral drugs for the treatment of alphavirus infections. Alphaviruses have positive‐strand RNA
Sainan Wang +2 more
wiley +1 more source
Brazilian Journal of Nephrology, 2020 In addition to liver disease, the hepatitis C virus (HCV) has been associated with autoimmune phenomena, such as mixed cryoglobulin and glomerulonephritis (GN). Until recently, both chronic hepatitis and HCV extra-hepatic manifestations were treated with
Raissa M Arruda +5 more
doaj +2 more sources
Liver International, Volume 45, Issue 1, January 2025.ABSTRACT Background Historically, hepatitis C virus (HCV) was difficult to treat among people with HIV. However, treatment with direct‐acting antivirals (DAAs) results in 90%–95% of people being cured. There is a need to understand why a proportion of people are not cured.
Brendan L. Harney +20 more
wiley +1 more source